The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

俄亥俄州立大学作为实验治疗临床试验网络的牵头学术组织 (LAO)

• 批准号: 10393089
• 负责人: SUSANNE M ARNOLD
• 金额: $ 10万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-12 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10393089
• 关键词: Advanced Malignant Neoplasm; Basic Science; Biomedical Research; Biopsy; Blood; Blood Circulation; Cancer Burden; Cancer Center; Cancer Therapy Evaluation Program; Catchment Area; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Comprehensive Cancer Center; Development; Discipline; Drug Combinations; Drug Kinetics; Early Therapeutic-Clinical Trials Network; Enrollment; Evaluation; Faculty; Funding; Goals; Home; Institutes; Institution; Investigational Drugs; Investigational Therapies; Kentucky; Laboratories; Laboratory Study; Lead; Leadership; Letters; Malignant Neoplasms; Methods; Modernization; Molecular; New Agents; North Carolina; Nursing Research; Ohio; Oncology; Patient Monitoring; Patient Selection; Patients; Pattern; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenomics; Phase; Physicians; Reporting; Research; Research Personnel; Resources; Sampling; Science; Scientist; Site; Testing; Tissues; Training; Underserved Population; Universities; Utah; Vocational Guidance; cancer cell; design; exhaust; experience; innovation; member; multidisciplinary; novel; novel drug combination; novel therapeutics; response; tumor

PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with strong collaborations between experienced investigators from multiple oncologic disciplines and a vibrant pattern of discovery in the basic sciences. The present consortium includes OSUCCC in collaboration with the University of Kentucky Markey Cancer Center (MCC) and the University of Utah Huntsman Cancer Institute (HCI) with whom they have had strong relationships in the past, and the University of North Carolina Lineberger Comprehensive Cancer Center (UNC LCCC) who joined LAO OH-007 one year ago. This application is being submitted to request additional funds for UNC, an Affiliated Organization to OSU, an ETCTN UM1 Lead Academic Organization. The funds will allow UNC to continue to participate in the ETCTN including leadership of two ETCTN studies led by Drs. Claire Dees and Joshua Zeidner (described in more detail below), continued accrual to ETCTN studies and participating in other activities including LOI submission and PTMA applications. The present proposal contains a request for funds to support the efforts of two research coordinators and two investigators. Going forward, there will be a continued concerted effort to incorporate the UNC LCCC group into the daily workings of its new home LAO so that study accrual and scientific discovery at this institution can be supported and enhanced. This consortium is committed to accruing a minimum of 100 patients per year to ETCTN studies and it is foreseen that the addition of the UNC LCC phase I group will contribute to this goal in a significant manner.

项目摘要 LAO OH-007 UM 1研究小组由一个经验丰富，创新的多学科团队组成， 科学家和临床研究人员致力于为癌症患者寻找有效的新疗法， 通过CTEP NCI提供的资源。俄亥俄州州立大学综合癌症中心 （OSUCCC）是一个综合性的生物医学研究校园，与经验丰富的 来自多个肿瘤学科的研究人员和基础科学领域充满活力的发现模式。的 目前的联盟包括OSUCCC与肯塔基州大学马基癌症中心的合作 (MCC)以及犹他州大学亨茨曼癌症研究所（HCI），他们与该研究所有着密切的关系 在过去，北卡罗来纳州Lineberger综合癌症中心（Lineberger Comprehensive Cancer Center） 一年前加入了LAO OH-007提交这一申请是为了要求为联合国儿童基金会提供额外资金， OSU的附属组织，ETCTN UM 1领先的学术组织。这些资金将使 继续参与ETCTN，包括领导由Claire Dees博士领导的两项ETCTN研究， 约书亚泽伊（下文更详细描述），继续参加ETCTN研究并参与其他研究 活动包括LOI提交和PTMA申请。本提案载有一项资金请求 支持两名研究协调员和两名调查员的工作。展望未来，将继续 协调一致的努力，以纳入其新的家园老挝的日常工作，使研究 该机构的收益和科学发现可以得到支持和加强。这个财团致力于 每年至少有100名患者参加ETCTN研究，可以预见， LCC第一阶段小组将为实现这一目标作出重大贡献。